BCL2 rs7226979: Understanding Genetic Associations in DLBCL
The rs7226979 variant is a single-nucleotide polymorphism located within the BCL2 gene. Research has investigated its potential association with survival outcomes in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP chemotherapy.
What each genotype means
Typical BCL2 genotype
This genotype represents the most common sequence variation observed in many populations for this specific location. Research into BCL2 variants often examines how these sequences influence the body's response to therapies like R-CHOP in lymphoma patients; however, evidence regarding this specific variant's clinical impact remains limited and is not currently used to guide treatment. Always discuss any concerns regarding medication efficacy or treatment planning with your oncologist or pharmacist.
This genotype is common, though specific frequencies vary significantly by ancestral background.
Variable BCL2 genotype
Carrying one copy of the T allele means your genetic profile at this location differs from the most common reference sequence. Studies investigating BCL2 polymorphisms in the context of DLBCL treatment seek to understand if such variations influence how patients respond to R-CHOP therapy, but findings are often preliminary or require further validation. Because this evidence is not definitive, this result should not influence your medical care; please consult your clinician or pharmacist regarding any questions about your treatment regimen.
This genotype is present in most populations but is relatively less common than the homozygous CC genotype in many ancestries.
Alternative BCL2 genotype
This genotype represents the homozygous state for the less common T allele at this position. While some BCL2 variants have been investigated for their potential role in treatment outcomes for patients with certain types of lymphoma, the clinical significance of this specific genotype remains a subject of ongoing research. As such, this information is not diagnostic and should not be used to alter medical treatment; please discuss any questions about your medications with your healthcare team.
This is the least common genotype for this variant across most documented populations.
What is rs7226979?
The rs7226979 variant is a specific genetic change, or single-nucleotide polymorphism (SNP), located in the BCL2 gene. In genomics, a SNP represents a variation at a single position in the DNA sequence among individuals. This particular variant is found within an intronic region of the BCL2 gene, meaning it is located in a non-coding section of the gene that does not directly provide instructions for making a protein. However, intronic variants can still influence how genes are regulated or expressed. Scientists study these variants to understand if they contribute to differences in disease susceptibility or how individuals respond to medical treatments. Because rs7226979 is a common variant, it is present in a significant portion of the population, making it a subject of interest in pharmacogenomic studies aimed at identifying genetic markers that might predict clinical outcomes in cancer patients.
The Role of the BCL2 Gene
The BCL2 gene provides instructions for producing the Bcl-2 protein, which plays a critical role in regulating apoptosis, or programmed cell death. Apoptosis is a natural process the body uses to eliminate damaged or unnecessary cells. In many types of cancer, including certain lymphomas, the BCL2 gene can become dysregulated, leading to an overproduction of the Bcl-2 protein. This prevents cancer cells from undergoing apoptosis, allowing them to survive and multiply uncontrollably. Because of this function, the BCL2 gene is a major target for therapeutic intervention. Several drugs, known as BCL-2 inhibitors, have been developed to block this protein and encourage cancer cells to die. Understanding how genetic variations like rs7226979 might influence the expression or function of BCL2 is an active area of research, as it may help explain why some patients respond differently to standard chemotherapy regimens.
Research and Evidence Strength
The association between rs7226979 and clinical outcomes in diffuse large B-cell lymphoma (DLBCL) has been explored in scientific literature, specifically regarding the efficacy of R-CHOP, a standard combination chemotherapy regimen. One study identified this SNP as a potential predictor for survival in patients undergoing this treatment. While these findings are notable, the evidence strength is currently considered moderate. Genetic association studies often face challenges, such as the need for large, diverse cohorts to confirm findings across different populations. Furthermore, cancer is a complex disease influenced by many genetic and environmental factors, not just a single SNP. Therefore, while rs7226979 is a documented marker in specific research contexts, it is not currently used as a standard diagnostic tool in clinical practice. Further large-scale validation is required to determine the clinical utility of this variant in guiding personalized treatment decisions.
Population Frequency
The frequency of the rs7226979 variant is variable across different ancestral populations. Genetic databases indicate that the distribution of the alleles for this SNP is not uniform globally, which is common for many human genetic variants. Because frequency data can fluctuate based on the specific population group being studied, researchers must account for ancestry when analyzing the impact of this variant. This variability underscores the importance of conducting diverse genetic studies to ensure that findings are applicable to a broad range of patients. Detailed frequency data for specific populations can typically be found in large-scale genomic repositories like gnomAD, which aggregate data from thousands of individuals worldwide to provide a clearer picture of how common specific genotypes are within different ethnic and geographic groups.
What This Information Means for You
It is important to understand that genetic variants like rs7226979 are subjects of scientific research and do not provide a definitive medical diagnosis or a guaranteed prediction of treatment response. If you or a loved one are undergoing treatment for lymphoma, it is essential to rely on the expertise of your oncology team. They utilize established clinical guidelines, diagnostic tests, and tumor profiling to determine the most appropriate therapeutic strategy. You should never make decisions about your medication or treatment plan based on genetic information found online. If you have questions about how your genetic profile might influence your care, discuss them directly with your clinician or a specialized pharmacist. They can provide context regarding the current state of research and explain how it applies—or does not apply—to your specific clinical situation.
How common is this variant?
The frequency of the rs7226979 variant is variable across different global populations, with specific allele distributions documented in large-scale genomic databases.
Frequently asked questions
Is rs7226979 a diagnostic test for lymphoma?
No, rs7226979 is not a diagnostic test for lymphoma. It is a genetic variant studied in research settings to understand potential associations with treatment outcomes, not to identify or diagnose the disease itself.
Can I use this SNP to predict if R-CHOP will work for me?
No, you cannot use this SNP to predict your response to R-CHOP. Treatment efficacy is determined by many complex factors, and this variant is currently only a subject of research, not a clinical tool for predicting individual patient outcomes.
Where can I find more information about BCL2 variants?
You can find more information about BCL2 and its variants through reputable scientific resources such as the NCBI Gene database, ClinVar, and the GWAS Catalog. These platforms provide peer-reviewed data on genetic associations.
Should I get my DNA tested for this variant?
There is no clinical recommendation to test for this variant. Genetic testing for specific SNPs should only be performed under the guidance of a healthcare professional if it is relevant to your specific medical care.
Sources & further reading
Educational information only, last refreshed 10/1/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs7226979?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29